GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mendus AB (CHIX:IMMUs) » Definitions » Loans Receivable

Mendus AB (CHIX:IMMUS) Loans Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mendus AB Loans Receivable?

Mendus AB's Loans Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Mendus AB Loans Receivable Historical Data

The historical data trend for Mendus AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mendus AB Loans Receivable Chart

Mendus AB Annual Data
Trend Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mendus AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mendus AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Mendus AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Mendus AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mendus AB (CHIX:IMMUS) Business Description

Traded in Other Exchanges
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company that focuses on the development of immunotherapies that address tumor recurrence and difficult-to-treat established tumors. Its operations consist of research and development for pharmaceuticals.

Mendus AB (CHIX:IMMUS) Headlines

No Headlines